Celanese’s (CE) collaboration with Secarna enables the development of a novel implant with the potential to significantly alter how disease-modifying ASO treatments are given.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok